FY27 standalone revenue target of ₹90 crore
Management expects base business (standalone) to reach ₹90 crore in FY27, implying ~20% growth over FY26 estimated ₹73-75 crore.
SANJIVANIPARANTERAL / guidance tracker
Keep management guidance in view.
Sanjivani Paranteral · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 SPL Infusion revenue target of ₹60-65 crore
The Pune IV fluids JV is expected to contribute ₹60-65 crore in FY27, up from ₹1.2 crore in Q3 FY26.
SPL Infusion capacity utilization to reach 40-50% by FY27
Current utilization is 23-27%; management targets 40-50% by FY27 as product approvals ramp up.
Base business EBITDA margin of 16-17% for FY26
Management expects standalone EBITDA margin to remain in the 16-17% range for the full year, consistent with 9-month trends.
FY27 Base Business Revenue Target
Management guided for base business revenue of ₹80-85 crore in FY27.
FY27 IV Facility Revenue Target
Management guided for Pune IV fluids plant revenue of ₹60-65 crore in FY27.
IV Facility EBITDA Margin Target
Management expects IV facility to achieve EBITDA margins of 17-18% on an annualized basis in FY27.
Base Business EBITDA Margin Guidance
Management guided base business EBITDA margins in the range of 15.5-16.5% for FY27.